The Challenge: TherapeutAix was contacted by an institution wanting to define areas to build capabilities. Their goal was to better complement expertise and to meet

The Challenge: TherapeutAix was approached by a small biotech company that operated in a fully virtual setting. To progress assets on a novel drug delivery

The Challenge: TherapeutAix was contacted by an innovative biotech company that was undertaking final preparations for First-in-Human clinical trials. It was known that their biologic

The Challenge: TherapeutAix was approached by a US-based biotech company to review an asset that they were considering repositioning for fibrotic disease. The company asked for

The Challenge: TherapeutAix was approached by a small virtual biotech to review a target and asset that for a rare fibrotic disease. The company asked for specific help in reviewing the target, existing data,

The Challenge: A small, highly virtualized biotech had identified an attractive target in fibrotic diseases and needed a translational strategy to generate clinical data that